CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 75-326

CHEMISTRY REVIEW(S)

Page(s) _______

Contain Trade Secret,

Commercial/Confidential

Information and are not
releasable.

Chemistry, #38, 2/12/99

Contain Trade Secret,

Commercial/Confidential

Information and are not releasable.

Chemistry, #38, 6/30/98

1. CHEMISTRY REVIEW NO 4

2. ANDA 75-326

3. NAME AND ADDRESS OF APPLICANT

Eon Labs Manufacturing, Inc. Attention: Sadie M. Ciganek 227-15 N. Conduit Avenue Laurelton, NY 11413

4. LEGAL BASIS FOR SUBMISSION

The reference listed drug's marketing exclusivity expired on 10/31/96. U.S. Patent # 4591592 will expire on 5/27/03. The firm has included a statement that their product will not infringe upon the above patent. As per 21 CFR 314.95(a) and (b), the firm has sent a notice of Certification to Syntex Inc.

5. SUPPLEMENT(s)

N/A

6. PROPRIETARY NAME

None

7. NONPROPRIETARY NAME

Ticlopidine Hydrochloride Tablets

8. SUPPLEMENT(s) PROVIDE(s) FOR:

N/A

9. <u>AMENDMENTS AND OTHER DATES:</u> Firm

Original filing - 1/30/98
New Correspondence - 3/20/98
Amendment - 4/30/98
Major amendment - 7/30/98
New correspondence - 3/4/99
Amendment - 3/17/99
Label amendment - 4/27/99
New correspondence - 6/22/99
Amendment - 6/28/99

FDA

ANDA acceptable for filing - 2/26/98
CMC, label deficiency fax - 6/30/98
Label letter re: educational program - 9/21/98
Bio specification for dissolution - 10/28/98
Chemistry deficiencies - 2/12/99
Phone call by K. Sherrod/chemist/TL with Firm/3/1/99
Labeling deficiencies - 3/11/99
Method validation results - 3/12/99
Chemistry deficiency -6/11/99
Label approval letter- 6/10/99
Label letter re: post-approval educational plan- 6/15/99

- 10. PHARMACOLOGICAL CATEGORY
 To reduce the risk of thrombotic
 stroke

 11. Rx or OTC
 Rx
- 12. RELATED IND/NDA/DMF(s)

13. <u>DOSAGE FORM</u>

Off-white, oval shaped film coated tablets with imprints E115 on one side and plain on the other side.

- 14. <u>POTENCY</u> 250 mg
- 15. <u>CHEMICAL NAME AND STRUCTURE</u>
 5-[(2-Chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c]
 pyridine hydrochloride

 M.W. = 300.25
- 16. RECORDS AND REPORTS

None

17. COMMENTS

None

18. CONCLUSIONS AND RECOMMENDATIONS

No outstanding Chemistry issues; approval recommended.

19. REVIEWER:

DATE COMPLETED:

Radhika Rajagopalan, Ph.D.

7/21/99

5/

101

8/6/99

Contain Trade Secret,

Commercial/Confidential

Information and are not releasable.

Chemistry #20-#37, 8/6/99